Shares of MacroCure Ltd. (NASDAQ:MCUR) have earned an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Brokers have set a 1-year consensus price target of $1.50 for the company, according to Zacks. Zacks has also given MacroCure an industry rank of 109 out of 265 based on the ratings given to its competitors.
Separately, Credit Suisse Group AG cut MacroCure from a “neutral” rating to an “underperform” rating and set a $1.00 target price on the stock. in a report on Monday, July 18th.
A hedge fund recently raised its stake in MacroCure stock. Renaissance Technologies LLC increased its stake in shares of MacroCure Ltd. (NASDAQ:MCUR) by 25.3% during the first quarter, according to its most recent filing with the SEC. The fund owned 186,500 shares of the company’s stock after buying an additional 37,700 shares during the period. Renaissance Technologies LLC owned approximately 1.12% of MacroCure worth $166,000 at the end of the most recent reporting period. 2.76% of the stock is currently owned by institutional investors.
Shares of MacroCure (NASDAQ:MCUR) opened at 1.59 on Wednesday. The company’s market cap is $28.16 million. MacroCure has a one year low of $0.75 and a one year high of $4.26. The firm’s 50-day moving average is $1.57 and its 200-day moving average is $1.33.
MacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.